Factoring nonviral gene therapy into a cure for hemophilia A

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 5, 2008, Pages 464-470

  Gabrovsky, V ^a   Calos, M P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Factor VIII; Gene therapy; Hemophilia A; Inhibitor antibodies; Nonviral DNA delivery; Plasmid DNA

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; INTEGRASE; LIPOSOME; NAKED DNA; NANOPARTICLE; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PLASMID DNA; POLYETHYLENEIMINE; POLYMER; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; TRANSPOSASE; VIRUS VECTOR;

BLEEDING TENDENCY; BONE MARROW TRANSPLANTATION; CANCER RISK; CELL BASED GENE THERAPY; CLINICAL TRIAL; CPG ISLAND; DNA VECTOR; DRUG WITHDRAWAL; ELECTROPORATION; GENE EXPRESSION; GENE INSERTION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEALTH CARE COST; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYDRODYNAMICS BASED TRANSFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERMETHOD COMPARISON; INTERVENTIONAL RADIOLOGY; INVERTED TERMINAL REPEAT; LIVER TOXICITY; MUTAGENESIS; NONHUMAN; NONVIRAL GENE THERAPY; PROMOTER REGION; REVIEW; THROMBOCYTOPENIA; TRANSGENE; TRANSPOSON; TREATMENT OUTCOME; ULTRASOUND; VIRAL GENE THERAPY;

CLINICAL TRIALS AS TOPIC; FACTOR VIII; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HUMANS; TRANSGENES;

ANIMALIA;

EID: 53249093884     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Liu L, Sanz S, Heggestad AD, Antharam V, Notterpek L, Fletcher BS: Endothelial targeting of the Sleeping Beauty transposon within lung. Mol Ther (2004) 10(1):97-105.
2. Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, Du LM, Desai D, Montgomery RR: Lentivirus-mediated platelet-derived Factor VIII gene therapy in murine haemophilia A. J Thromb Haemost (2007) 5(2):352-361. •• This represents an elegant study demonstrating phenotypic cure in hemophilia A mice, despite high-titer antibodies against human Factor VIII. Factor VIII production was limited to platelets and released at the site of injury.
3. Pipe SW: The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost (2005) 3(8):1692-1701.
4. Hough C, Lillicrap D: Gene therapy for hemophilia: An imperative to succeed. J Thromb Haemost (2005) 3(6):1195-1205.
5. Roth DA, Tawa NE Jr, O'Brien JM, Treco DA, Selden RF: Nonviral transfer of the gene encoding coagulation Factor VIII in patients with severe hemophilia A. N Engl J Med (2001) 344(23):1735-1742. •• This ex vivo strategy is currently the only nonviral gene therapy study in hemophilia A patients. The clinical trial was initially successful, but did not result in long-term expression of FVIII.
6. Uhl L: Infectious risks of blood transfusion. Curr Hematol Rep (2002) 1(2):156-162.
7. Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW: Bioengineering of coagulation Factor VIII for improved secretion. Blood (2004) 103(9):3412-3419.
8. Miao CH, Ye P, Thompson AR, Rawlings DJ, Ochs HD: Immunomodulation of transgene responses following naked DNA transfer of human Factor VIII into hemophilia A mice. Blood (2006) 108(1):19-27.
9. Branch DW, Rodgers GM: Recombinant activated Factor VII: A new weapon in the fight against hemorrhage. Obstet Gynecol (2003) 101(6):1155-1156.
10. Gao X, Kim KS, Liu D: Nonviral gene delivery: What we know and what is next. AAPSJ (2007) 9(1):E92-E104.
11. Pierce GF, Lillicrap D, Pipe SW, Vandendriessche T: Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J Thromb Haemost (2007) 5(5):901-906.
12. Powell JS, Ragni MV, White GC 2nd, Lusher JM, Hillman-Wiseman C, Moon TE, Cole V, Ramanathan-Girish S, Roehl H, Sajjadi N, Jolly DJ et al: Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood (2003) 102(6):2038-2045.
13. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2003) 348(3):255-256.
14. VandenDriessche T, Collen D, Chuah MK: Biosafety of onco-retroviral vectors. Curr Gene Ther (2003) 3(6):501-515.
15. Liu Q, Muruve DA: Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther (2003) 10(11):935-940.
16. Liu Q, Zaiss AK, Colarusso P, Patel K, Haljan G, Wickham TJ, Muruve DA: The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther (2003) 14(7):627-643.
17. Scallan CD, Liu T, Parker AE, Patarroyo-White SL, Chen H, Jiang H, Vargas J, Nagy D, Powell SK, Wright JF, Sarkar R et al: Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood (2003) 102(12):3919- 3926.
18. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M et al: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 12(3):342-347.
19. Chen J, Wu Q, Yang P, Hsu HC, Mountz JD: Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy. Mol Ther (2006) 13(2):260-269.
20. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, Couto LB, Pierce GF: Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood (2006) 107(5):1810-1817.
21. Vandendriessche T, Thorrez L, Acosta-Sanchez A, Petrus I, Wang L, Ma L, De Waele L, Iwasaki Y, Gillijns V, Wilson JM, Collen D et al: Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost (2007) 5(1):16-24.
22. Ponder KP: Gene therapy for hemophilia. Curr Opin Hematol (2006) 13(5):301-307.
23. Gan SU, Kon OL, Calne RY: Genetic engineering for haemophilia A. Expert Opin Biol Ther (2006) 6(10):1023-1030.
24. Lim WH, Russ GR, Coates PT: Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology (Carlton) (2006) 11(4):355-366.
25. Nakai H, Montini E, Fuess S, Storm TA, Grompe M, Kay MA: AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 34(3):297-302.
26. Chen ZY, He CY, Ehrhardt A, Kay MA: Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther (2003) 8(3):495-500.
27. McMahon JM, Wells KE, Bamfo JE, Cartwright MA, Wells DJ: Inflammatory responses following direct injection of plasmid DNA into skeletal muscle. Gene Ther (1998) 5(9):1283-1290.
28. Budker VG, Subbotin VM, Budker T, Sebestyén MG, Zhang G, Wolff JA: Mechanism of plasmid delivery by hydrodynamic tail vein injection. II. Morphological studies. J Gene Med (2006) 8(7):874-888.
29. Suda T, Gao X, Stolz DB, Liu D: Structural impact of hydrodynamic injection on mouse liver. Gene Ther (2007) 14(2):129-137.
30. Hodges BL Scheule RK: Hydrodynamic delivery of DNA. Expert Opin Biol Ther (2003) 3(6):911-918.
31. Herweijer H, Wolff JA: Gene therapy progress and prospects: Hydrodynamic gene delivery. Gene Ther (2007) 14(2):99-107. •• An important and comprehensive review of the hydrodynamic method for nonviral gene delivery.
32. Eastman SJ, Baskin KM, Hodges BL, Chu Q, Gates A, Dreusicke R, Anderson S, Scheule RK: Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Hum Gene Ther (2002) 13(17):2065-2077.
33. Aliño SF, Herrero MJ, Noguera I, Dasí F, Sánchez M: Pig liver gene therapy by noninvasive interventionist catheterism. Gene Ther (2007) 14(4):334-343. • This successful large-animal study demonstrated a modification of hydrodynamic injection in pigs for delivery of nonviral DNA to the liver. The study suggested that the method could be further manipulated for use in humans.
34. Aihara H, Miyazaki J: Gene transfer into muscle by electroporation in vivo. Nat Biotechnol (1998) 16(9):867-870.
35. Dean DA, Machado-Aranda D, Blair-Parks K, Yeldandi AV, Young JL: Electroporation as a method for high-level nonviral gene transfer to the lung. Gene Ther (2003) 10(18):1608-1615.
36. McMahon JM, Wells DJ: Electroporation for gene transfer to skeletal muscles: Current status. BioDrugs (2004) 18(3):155-165.
37. Manome Y, Nakamura M, Ohno T, Furuhata H: Ultrasound facilitates transduction of naked plasmid DNA into colon carcinoma cells in vitro and in vivo. Hum Gene Ther (2000) 11(11):1521-1528.
38. Taniyama Y, Tachibana K, Hiraoka K, Aoki M, Yamamoto S, Matsumoto K, Nakamura T, Ogihara T, Kaneda Y, Morishita R: Development of safe and efficient novel nonviral gene transfer using ultrasound: Enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther (2002) 9(6):372-380.
39. Shea LD, Smiley E, Bonadio J, Mooney DJ: DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol (1999) 17(6):551-554.
40. Segura T, Volk MJ, Shea LD: Substrate-mediated DNA delivery: Role of the cationic polymer structure and extent of modification. J Control Release (2003) 93(1):69-84.
41. Jang JH, Shea LD: Controllable delivery of non-viral DNA from porous scaffolds. J Control Release (2003) 86(1):157-168.
42. Segura T, Shea LD: Surface-tethered DNA complexes for enhanced gene delivery. Bioconjug Chem (2002) 13(3):621-629.
43. Pannier AK, Shea LD: Controlled release systems for DNA delivery. Mol Ther (2004) 10(1):19-26.
44. Gomez-Vargas A, Hortelano G: Nonviral gene therapy approaches to hemophilia. Semin Thromb Hemost (2004) 30(2):197-204.
45. Olivares EC, Hollis RP, Chalberg TW, Meuse L, Kay MA, Calos MP: Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol (2002) 20(11):1124-1128. • In this study, Factor IX expression was achieved in mice using the φC31 integrase system and demonstrated the specificity of this integrase for pseudo attP sites in the murine genome.
46. Miao CH, Ye X, Thompson AR: High-level Factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors. Hum Gene Ther (2003) 14(14):1297-1305.
47. Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA: Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet (2000) 25(1):35-41.
48. Liu L, Mah C, Fletcher BS: Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon. Mol Ther (2006) 13(5):1006-1015.
49. Ye P, Thompson AR, Sarkar R, Shen Z, Lillicrap DP, Kaufman RJ, Ochs HD, Rawlings DJ, Miao CH: Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther (2004) 10(1):117-126.
50. West LJ: Defining critical windows in the development of the human immune system. Hum Exp Toxicol (2002) 21(9-10):499-505.
51. West LJ: Developmental aspects of immunomodulation: Exploiting the immature immune system for organ transplantation. Transpl Immunol (2002) 9(2-4):149-153.
52. Ohlfest JR, Frandsen JL, Fritz S, Lobitz PD, Perkinson SG, Clark KJ, Nelsestuen G, Key NS, McIvor RS, Hackett PB, Largaespada DA: Phenotypic correction and long-term expression of Factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood (2005) 105(7):2691-2698. • This study demonstrated that immunotolerization of neonatal hemophilia A mice decreased the subsequent immune response to Factor VIII gene therapy.
53. Chalberg TW, Genise HL, Vollrath D, Calos MP: φC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest Ophthalmol Vis Sci (2005) 46(6):2140-2146.
54. Chalberg TW, Portlock JL, Olivares EC, Thyagarajan B, Kirby PJ, Hillman RT, Hoelters J, Calos MP: Integration specificity of phage φC31 integrase in the human genome. J Mol Biol (2006) 357(1):28-48.
55. Sclimenti CR, Thyagarajan B, Calos MP: Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucleic Acids Res (2001) 29(24):5044-5051.
56. Ehrhardt A, Xu H, Huang Z, Engler JA, Kay MA: A direct comparison of two nonviral gene therapy vectors for somatic integration: In vivo evaluation of the bacteriophage integrase φC31 and the Sleeping Beauty transposase. Mol Ther (2005) 11(5):695-706.
57. Hansson K, Stenflo J: Post-translational modifications in proteins involved in blood coagulation. J Thromb Haemost (2005) 3(12):2633-2648. • This paper provides an excellent review of issues confronting successful expression of blood coagulation proteins.
58. Miao CH, Ohashi K, Patijn GA, Meuse L, Ye X, Thompson AR, Kay MA: Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic Factor IX gene expression in vivo but not in vitro. Mol Ther (2000) 1(6):522-532.
59. Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P: The humoral response to human Factor VIII in hemophilia A mice. J Thromb Haemost (2007) 5(3):512-519. • In a review of the immune reaction to Factor VIII in hemophilia A mice, this study suggested possible targets for reducing this response.
60. Bril WS, van Helden PM, Hausl C, Zuurveld MG, Ahmad RU, Hollestelle MJ, Reitsma PH, Fijnvandraat K, van Lier RA, Schwarz HP, Mertens K et al: Tolerance to Factor VIII in a transgenic mouse expressing human Factor VIII cDNA carrying an Arg593 to Cys substitution. Thromb Haemost (2006) 95(2):341-347.
61. Parker ET, Healey JF, Barrow RT, Craddock HN, Lollar P: Reduction of the inhibitory antibody response to human Factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood (2004) 104(3):704-710.
62. Lei TC, Scott DW: Induction of tolerance to Factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood (2005) 105(12):4865-4870.
63. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP: Rituximab in the treatment of acquired Factor VIII inhibitors. Blood (2002) 100(9):3426-3428.
64. Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA et al: Factor VIII ectopically expressed in platelets: Efficacy in hemophilia A treatment. Blood (2003) 102(12):4006-4013.